Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia

Clinical Trial ID NCT00005596

PubWeight™ 23.31‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00005596

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 2008 5.49
2 Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol 2012 5.08
3 Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2011 3.13
4 Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 2012 2.09
5 Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood 2012 1.90
6 ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2012 1.39
7 Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood 2012 1.17
8 Dexamethasone alters sleep and fatigue in pediatric patients with acute lymphoblastic leukemia. Cancer 2007 1.16
9 Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008 1.05
10 A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood 2014 1.04
11 Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia. J Clin Oncol 2016 0.79
Next 100